8-K 1 ea146694-8k_oramed.htm CURRENT REPORT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 30, 2021

 

ORAMED PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE   001-35813   98-0376008
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

1185 Avenue of the Americas, Third Floor, New York, New York   10036
(Address of Principal Executive Offices)   (Zip Code)

 

844-967-2633

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.012   ORMP   The Nasdaq Capital Market, Tel Aviv Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On August 30, 2021, Oramed Pharmaceuticals Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "2021 Annual Meeting"). The final voting results at the 2021 Annual Meeting are set forth below.

 

Proposal No. 1 — Re-election of Directors.

 

The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows:

 

Director Name  For   Against   Abstain   Broker Non-Votes 
                 
Aviad Friedman   11,705,383    518,842    803,711   - 
                    
Dr. Miriam Kidron   11,453,419    776,749    797,768   - 
                    
Nadav Kidron   11,933,630    294,042    800,264   - 
                    
Dr. Arie Mayer   10,892,473    1,321,078    814,385   - 
                    
Kevin Rakin   10,155,935    2,056,527    815,474   - 
                    
Leonard Sank   11,834,896    367,860    825,180   - 

 

Proposal No. 2 — Ratification of the Prior Approval of the 2019 Incentive Plan.

 

The stockholders ratified the prior approval of the Company’s 2019 Stock Incentive Plan. The votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
             
 9,197,665    2,984,635    845,636    - 

 

Proposal No. 3 — Ratification of the Prior Approval of the Amended and Restated 2019 Incentive Plan.

 

The stockholders ratified the prior approval of the Company’s Amended and Restated 2019 Stock Incentive Plan. The votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
             
 9,183,977    2,978,838    865,121    - 

 

Proposal No. 4 — Ratification of the Re-election of Aviad Friedman, Xiaoming Gao, Miriam Kidron, Nadav Kidron, Arie Mayer, Kevin Rakin and Leonard Sank as Directors of the Company.

 

The stockholders ratified the re-election of Aviad Friedman, Xiaoming Gao, Miriam Kidron, Nadav Kidron, Arie Mayer, Kevin Rakin and Leonard Sank as directors of the Company. The votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
             
 11,517,909    687,325    822,702    - 

 

Proposal No. 5 — Amendment to the Company’s Certificate of Incorporation to Effect a Staggered Board Structure.

 

The stockholders did not approve an amendment to the Company’s Certificate of Incorporation to effect a staggered board structure. The votes were as follows:

 

For   Against   Abstain   Broker Non-Votes 
             
 8,157,257    4,085,313    785,366    - 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ORAMED PHARMACEUTICALS INC.
     
  By: /s/ Nadav Kidron
  Name: Nadav Kidron
  Title: President and CEO

 

August 31, 2021

 

 

2